Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias
CD27-CD70 interactions in the pathogenesis of Waldenstrom's Macroglobulinemia
Clinical relevance of soluble HLA class I molecules in Waldenstrom's Macroglobulinemia
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia
Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia
Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia
Increased Incidence of Transformation and Myelodysplasia/Acute Leukemia in Patients With Waldenström Macroglobulinemia Treated With Nucleoside Analogs
Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom's macroglobulinemia
Long term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia
Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia
Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia
Targeting NF-kappaB in Waldenstrom macroglobulinemia
Thalidomide and rituximab in Waldenstrom's macroglobulinemia
The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia
Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's Macroglobulinemia